Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Dexcom Inc. said today that the FDA approved new “artificial pancreas” software for its G4 Platinum continuous glucose monitor.
San Diego-based DexCom said its new Software 505 “features the same advanced algorithm as used in artificial pancreas research around the world.” Read more
EDAP said today that the FDA sent it a “not approvable” letter over the Ablatherm prostate cancer treatment it’s trying to get approved for the U.S. market.
But the federal watchdog agency’s Center for Devices & Radiological Health left the door open for another run at pre-market approval, the French medical device maker said, recommending a narrower indication for Ablatherm. Read more
Second Sight Medical said that it plans to raise $31.5 million in an initial public offering, likely next week.
Second Sight created the Argus II “bionic eye,” the 1st retinal prosthesis approved for sale by the FDA. Read more